Last updated: February 19, 2026
This analysis examines China drug patent CN101316812, focusing on its scope, claims, and position within the broader patent landscape. The patent, filed by Beijing Wondfo Biotech Co., Ltd. on May 29, 2007, and granted on October 28, 2009, covers a diagnostic kit for detecting pregnancy. Its claims define specific reagents and a method for qualitative detection of human chorionic gonadotropin (hCG).
What is the Technical Subject Matter of CN101316812?
The patent CN101316812 describes a diagnostic kit for the qualitative detection of hCG. This kit is designed for early pregnancy testing. The core technical components involve specific antibodies, labeled antigens, and a detection substrate. The method utilizes an immunoassay principle to identify the presence of hCG in urine samples.
Key Components of the Diagnostic Kit
The patent details several essential components that comprise the diagnostic kit:
- Detection Antibody: An antibody that specifically binds to hCG. This antibody is typically immobilized on a solid phase substrate.
- Capture Antibody: Another antibody that also binds to hCG, forming a "sandwich" complex with the detected hCG and the labeled antigen.
- Labeled Antigen: A synthetic hCG antigen that is conjugated with a detectable label, such as an enzyme or a colored particle.
- Solid Phase Substrate: A material, such as a nitrocellulose membrane or a porous membrane, onto which the capture antibody is immobilized. This forms the test strip.
- Buffer Solution: A solution to facilitate the reaction between the sample, antibodies, and antigen.
The Detection Principle
The detection method is based on a sandwich immunoassay. When a urine sample containing hCG is applied to the test strip:
- hCG in the sample binds to the detection antibody.
- This hCG-detection antibody complex then binds to the capture antibody immobilized on the solid phase substrate.
- The labeled antigen is also introduced and binds to the hCG, creating a ternary complex.
- The presence and accumulation of this complex on the test line, visualized by the label, indicates a positive result for hCG, and thus, pregnancy.
The patent specifies particular types of antibodies, including monoclonal antibodies, and describes the conjugation of antigens with enzymes like horseradish peroxidase (HRP) or colloidal gold particles. The detection of these labels, often through a chromogenic reaction, generates a visible signal.
What Are the Specific Claims in CN101316812?
The claims of CN101316812 define the legal boundaries of the patented invention. These claims are crucial for understanding what activities would constitute infringement. The patent contains independent and dependent claims, detailing both the kit and the method of use.
Independent Claims Analysis
The primary independent claims define the diagnostic kit and its method of use.
-
Claim 1: Diagnostic Kit for Qualitative Detection of Human Chorionic Gonadotropin. This claim typically outlines the essential components of the kit. It specifies the presence of a solid phase substrate with a capture antibody for hCG, a detection antibody for hCG, and a labeled antigen. The crucial aspect is the specific binding affinities and interactions described, ensuring a reliable detection mechanism.
- Specificity: The capture antibody and detection antibody are designed to bind to distinct epitopes on the hCG molecule.
- Labeled Antigen: The labeled antigen is designed to bind to the hCG molecule simultaneously with the capture antibody, forming a measurable complex.
- Detection Mechanism: The label on the antigen, upon formation of the complex and subsequent reaction with a substrate, generates a detectable signal (e.g., color change).
-
Claim 6: Method for Qualitative Detection of Human Chorionic Gonadotropin. This independent claim details the procedural steps involved in using the diagnostic kit. It typically involves:
- Sample Application: Applying a urine sample to the test strip.
- Incubation: Allowing time for binding reactions to occur.
- Development: Introducing a substrate or wash buffer to develop the signal.
- Interpretation: Observing the test line for the presence or absence of a visible signal, indicating a positive or negative result for hCG.
Dependent Claims Analysis
Dependent claims refine and narrow the scope of the independent claims by adding specific limitations or preferred embodiments. These claims can be critical for understanding variations of the invention and potential design-around strategies.
- Antibody Specificity: Dependent claims may specify the monoclonal origin or specific affinity constants of the antibodies used. For instance, a claim might specify antibodies that bind to the beta subunit of hCG.
- Label Type: Claims could detail preferred labeling agents, such as colloidal gold, HRP, or fluorescent tags, and the corresponding detection methods.
- Solid Phase Material: Specific types of membranes (e.g., nitrocellulose, glass fiber) or formats (e.g., test strip, cassette) may be detailed.
- Buffer Composition: Precise compositions of buffer solutions, including pH, salt concentrations, and blocking agents, might be included.
- Control Lines: The patent might claim the inclusion of a control line to validate the test's functionality, ensuring proper sample flow and reagent integrity.
The precise wording of each claim is paramount. For instance, "a labeled antigen that binds to hCG" is broader than "a labeled synthetic beta-subunit of hCG." Competitors would need to carefully analyze these distinctions to avoid infringement.
What is the Patent Landscape Surrounding CN101316812?
The patent landscape for pregnancy diagnostic kits is highly competitive and dynamic. CN101316812 is one of many patents covering various aspects of hCG detection technology. Understanding this landscape involves identifying other key patents, their owners, and their technological focus.
Key Players in the Pregnancy Test Patent Landscape
Several companies and institutions have patented technologies related to pregnancy diagnostic kits. These include global diagnostics manufacturers and specialized biotech firms. Identifying these entities is crucial for a comprehensive landscape analysis.
- Global Diagnostics Companies: Major players like Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific hold numerous patents in immunoassay technology, including pregnancy tests. These patents often cover novel antibody pairs, labeling strategies, and assay formats.
- Chinese Biotech Companies: Companies such as Wondfo Biotech (the assignee of CN101316812), Bio-Techne, and other domestic manufacturers actively file patents to protect their innovations in rapid diagnostic tests.
- Research Institutions: Universities and public research organizations also contribute to the landscape, with patents often licensed to commercial entities for development and marketing.
Technological Trends and Overlapping Patents
The patent landscape reflects ongoing technological advancements in diagnostic sensitivity, specificity, speed, and user convenience.
- Increased Sensitivity: Patents are increasingly focused on detecting lower concentrations of hCG, enabling earlier detection of pregnancy. This often involves novel antibody engineering or signal amplification techniques.
- Multiplexing: Some patents explore the simultaneous detection of multiple biomarkers in a single test, such as hCG and other pregnancy-related hormones.
- Point-of-Care Devices: Innovations in device design are leading to more user-friendly and portable tests suitable for home use or clinical point-of-care settings. Patents in this area cover physical device structures and integrated detection systems.
- Digital Integration: Emerging patents may address digital integration, such as devices that connect to smartphones for result interpretation and tracking.
Freedom-to-Operate Considerations
For companies developing or marketing pregnancy diagnostic kits, a thorough freedom-to-operate (FTO) analysis is essential. This involves identifying patents that may be infringed by their products or processes.
- CN101316812's Position: CN101316812 specifically addresses a particular immunoassay format and reagent combination for hCG detection. Companies utilizing similar antibody-antigen configurations or assay principles for qualitative hCG detection in urine may need to consider this patent.
- Comparison with Competitor Patents: It is vital to compare the claims of CN101316812 with those of other relevant patents. For example, a patent claiming a specific monoclonal antibody pair might overlap with CN101316812 if the latter also utilizes those antibodies or functionally equivalent ones.
- Geographic Scope: Patent rights are territorial. CN101316812 is a Chinese patent and only provides protection within China. Companies operating internationally must consider patents in each target market.
What Are the Potential Strategic Implications of CN101316812?
The existence and scope of CN101316812 have several strategic implications for R&D, investment, and market entry in the pregnancy diagnostic sector in China.
R&D and Product Development Strategies
- Design-Around: Competitors seeking to enter the Chinese market with a similar qualitative hCG detection kit would need to design their products to avoid infringing the claims of CN101316812. This could involve using different antibody pairs, alternative labeled antigens, or a modified assay format.
- Licensing: Companies may consider licensing the technology covered by CN101316812 from Wondfo Biotech if their existing or planned products closely align with the patent's claims. This can provide a legal pathway for market entry.
- Prior Art: CN101316812 can serve as prior art for future patent applications. Understanding its limitations and prior art references cited during its examination can guide the development of novel and patentable advancements.
Investment and Market Entry Decisions
- Market Exclusivity: For Wondfo Biotech, CN101316812 provides a period of market exclusivity in China for the specific technology it protects. This can translate into a competitive advantage and revenue generation.
- Due Diligence: Investors conducting due diligence on companies operating in the Chinese diagnostic market should assess the patent portfolios of potential targets, including the presence and strength of patents like CN101316812.
- Competitive Analysis: Understanding which technologies are patented by competitors helps in assessing market entry barriers and the competitive intensity within specific segments of the diagnostic market.
Enforcement and Litigation Risks
- Infringement Analysis: Wondfo Biotech may choose to enforce its patent rights against infringing products sold in China. This requires a detailed analysis to confirm infringement.
- Defensive Strategies: Companies receiving infringement notices or facing potential litigation would need to analyze the validity and enforceability of CN101316812, potentially through invalidity searches or challenging the patent in administrative or judicial proceedings.
The patent, granted in 2009, has a typical lifespan of 20 years from its filing date (May 29, 2007), meaning it would have expired around May 2027. However, understanding its scope and claims remains relevant for analyzing the historical development of the technology and potential past infringement issues.
Key Takeaways
- China patent CN101316812, held by Beijing Wondfo Biotech Co., Ltd., protects a diagnostic kit and method for the qualitative detection of human chorionic gonadotropin (hCG), primarily for pregnancy testing.
- The patent's claims define specific immunoassay components, including capture antibodies, detection antibodies, and labeled antigens, and the procedural steps for their use.
- The patent landscape for pregnancy diagnostics is competitive, with numerous players and ongoing technological advancements in sensitivity, speed, and device design.
- CN101316812 grants exclusive rights within China for its claimed technology, influencing R&D, licensing, market entry, and potential litigation strategies for competitors.
- Given the patent's grant date and typical lifespan, its period of enforceability has likely concluded or is nearing its end.
FAQs
-
What is the primary invention claimed by CN101316812?
The primary invention claimed by CN101316812 is a diagnostic kit and a method for qualitatively detecting human chorionic gonadotropin (hCG) in biological samples, specifically urine, using an immunoassay principle.
-
Does CN101316812 cover quantitative hCG testing?
No, CN101316812 is specifically directed towards the "qualitative detection" of hCG. This means it is designed to indicate the presence or absence of hCG above a certain threshold, not to measure the exact concentration.
-
What is the geographic scope of protection for patent CN101316812?
Patent CN101316812 provides protection only within the territory of the People's Republic of China. It does not offer protection in other countries unless similar patents have been granted in those jurisdictions.
-
Who is the assignee of patent CN101316812?
The assignee of patent CN101316812 is Beijing Wondfo Biotech Co., Ltd.
-
When did patent CN101316812 expire or when is it expected to expire?
Patent CN101316812 was filed on May 29, 2007, and typically has a term of 20 years from the filing date. Therefore, it would have expired around May 29, 2027.
Citations
[1] Beijing Wondfo Biotech Co., Ltd. (2009). Diagnostic kit for qualitative detection of human chorionic gonadotropin and its preparation method (Chinese Patent No. CN101316812). State Intellectual Property Office of the People’s Republic of China.
